Literature DB >> 14523021

Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway.

Mara Fornaro1, Janet Plescia, Sophie Chheang, Giovanni Tallini, Yong-M Zhu, Michael King, Dario C Altieri, Lucia R Languino.   

Abstract

Integrins are cell surface heterodimeric transmembrane receptors that, in addition to mediating cell adhesion to extracellular matrix proteins modulate cell survival. This mechanism may be exploited in cancer where evasion from apoptosis invariably contributes to cellular transformation. The molecular mechanisms responsible for matrix-induced survival signals begin to be elucidated. Here we report that the inhibitor of apoptosis survivin is expressed in vitro in human prostate cell lines with the highest levels present in aggressive prostate cancer cells such as PC3 and LNCaP-LN3 as well as in vivo in prostatic adenocarcinoma. We also show that interference with survivin in PC3 prostate cancer cells using a Cys84--> Ala dominant negative mutant or survivin antisense cDNA causes nuclear fragmentation, hypodiploidy, cleavage of a 32-kDa proform caspase-3 to active caspase-3, and proteolysis of the caspase substrate poly(ADP-ribose) polymerase. We demonstrate that in the aggressive PC3 cell line, adhesion to fibronectin via beta1 integrins results in up-regulation of survivin and protection from apoptosis induced by tumor necrosis factor-alpha (TNF-alpha). In contrast, survivin is not up-regulated by cell adhesion in the non-tumorigenic LNCaP cell line. Dominant negative survivin counteracts the ability of fibronectin to protect cells from undergoing apoptosis, whereas wild-type survivin protects non-adherent cells from TNF-alpha-induced apoptosis. Evidence is provided that expression of beta1A integrin is necessary to protect non-adherent cells transduced with survivin from TNF-alpha-induced apoptosis. In contrast, the beta1C integrin, which contains a variant cytoplasmic domain, is not able to prevent apoptosis induced by TNF-alpha in non-adherent cells transduced with survivin. Finally, we show that regulation of survivin levels by integrins are mediated by protein kinase B/AKT. These findings indicate that survivin is required to maintain a critical anti-apoptotic threshold in prostate cancer cells and identify integrin signaling as a crucial survival pathway against death receptor-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523021     DOI: 10.1074/jbc.M307627200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.

Authors:  Lei Zhang; Guiying Wang; Lin Wang; Chenlin Song; Ye Leng; Xinhua Wang; Jiuhong Kang
Journal:  Mol Cell Biochem       Date:  2011-09-30       Impact factor: 3.396

2.  Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype.

Authors:  Amrita Singh; Carmine Fedele; Huimin Lu; Marja T Nevalainen; James H Keen; Lucia R Languino
Journal:  Mol Cancer Res       Date:  2016-07-20       Impact factor: 5.852

3.  Integrin-dependent amplification of the G2 arrest induced by ionizing radiation.

Authors:  Celeste L Kremer; Monika Schmelz; Anne E Cress
Journal:  Prostate       Date:  2006-01-01       Impact factor: 4.104

Review 4.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.

Authors:  Dimitra Bourboulia; William G Stetler-Stevenson
Journal:  Semin Cancer Biol       Date:  2010-05-12       Impact factor: 15.707

Review 5.  Regulation of Lymph Node Vascular-Stromal Compartment by Dendritic Cells.

Authors:  Dragos C Dasoveanu; William D Shipman; Jennifer J Chia; Susan Chyou; Theresa T Lu
Journal:  Trends Immunol       Date:  2016-09-13       Impact factor: 16.687

6.  Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.

Authors:  Iñigo Valiente-Alandi; Sarah J Potter; Ane M Salvador; Allison E Schafer; Tobias Schips; Francisco Carrillo-Salinas; Aaron M Gibson; Michelle L Nieman; Charles Perkins; Michelle A Sargent; Jiuzhou Huo; John N Lorenz; Tony DeFalco; Jeffery D Molkentin; Pilar Alcaide; Burns C Blaxall
Journal:  Circulation       Date:  2018-09-18       Impact factor: 29.690

7.  Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells.

Authors:  Guixia Wang; Kashif A Ahmad; Nathan H Harris; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2008-06-24       Impact factor: 3.396

8.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

9.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

Review 10.  Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy.

Authors:  G Chometon; V Jendrossek
Journal:  Clin Transl Oncol       Date:  2009-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.